Browse LPAR1

Summary
SymbolLPAR1
Namelysophosphatidic acid receptor 1
Aliases rec.1.3; vzg-1; Gpcr26; Mrec1.3; LPA1; endothelial differentiation, lysophosphatidic acid G-protein-coupled ......
Chromosomal Location9q
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Cell surface Cell membrane Multi-pass membrane protein Endosome Note=Prior to LPA treatment found predominantly at the cell surface. Internalized after LPA treatment. Colocalizes with RALA in endocytic vesicles after LPA treatment.
Domain PF00001 7 transmembrane receptor (rhodopsin family)
Function

Receptor for lysophosphatidic acid (LPA) (PubMed:9070858, PubMed:19306925, PubMed:25025571, PubMed:26091040). Plays a role in the reorganization of the actin cytoskeleton, cell migration, differentiation and proliferation, and thereby contributes to the responses to tissue damage and infectious agents. Activates downstream signaling cascades via the G(i)/G(o), G(12)/G(13), and G(q) families of heteromeric G proteins. Signaling inhibits adenylyl cyclase activity and decreases cellular cAMP levels (PubMed:26091040). Signaling triggers an increase of cytoplasmic Ca(2+) levels (PubMed:19656035, PubMed:19733258, PubMed:26091040). Activates RALA; this leads to the activation of phospholipase C (PLC) and the formation of inositol 1,4,5-trisphosphate (PubMed:19306925). Signaling mediates activation of down-stream MAP kinases (By similarity). Contributes to the regulation of cell shape. Promotes Rho-dependent reorganization of the actin cytoskeleton in neuronal cells and neurite retraction (PubMed:26091040). Promotes the activation of Rho and the formation of actin stress fibers (PubMed:26091040). Promotes formation of lamellipodia at the leading edge of migrating cells via activation of RAC1 (By similarity). Through its function as lysophosphatidic acid receptor, plays a role in chemotaxis and cell migration, including responses to injury and wounding (PubMed:18066075, PubMed:19656035, PubMed:19733258). Plays a role in triggering inflammation in response to bacterial lipopolysaccharide (LPS) via its interaction with CD14. Promotes cell proliferation in response to lysophosphatidic acid. Required for normal skeleton development. May play a role in osteoblast differentiation. Required for normal brain development. Required for normal proliferation, survival and maturation of newly formed neurons in the adult dentate gyrus. Plays a role in pain perception and in the initiation of neuropathic pain (By similarity).

> Gene Ontology
 
Biological Process GO:0000187 activation of MAPK activity
GO:0006140 regulation of nucleotide metabolic process
GO:0006164 purine nucleotide biosynthetic process
GO:0006171 cAMP biosynthetic process
GO:0006874 cellular calcium ion homeostasis
GO:0006875 cellular metal ion homeostasis
GO:0007015 actin filament organization
GO:0007187 G-protein coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger
GO:0007188 adenylate cyclase-modulating G-protein coupled receptor signaling pathway
GO:0007193 adenylate cyclase-inhibiting G-protein coupled receptor signaling pathway
GO:0007200 phospholipase C-activating G-protein coupled receptor signaling pathway
GO:0007202 activation of phospholipase C activity
GO:0007204 positive regulation of cytosolic calcium ion concentration
GO:0007249 I-kappaB kinase/NF-kappaB signaling
GO:0007265 Ras protein signal transduction
GO:0007266 Rho protein signal transduction
GO:0007272 ensheathment of neurons
GO:0008360 regulation of cell shape
GO:0008366 axon ensheathment
GO:0009150 purine ribonucleotide metabolic process
GO:0009152 purine ribonucleotide biosynthetic process
GO:0009165 nucleotide biosynthetic process
GO:0009187 cyclic nucleotide metabolic process
GO:0009190 cyclic nucleotide biosynthetic process
GO:0009260 ribonucleotide biosynthetic process
GO:0010001 glial cell differentiation
GO:0010517 regulation of phospholipase activity
GO:0010518 positive regulation of phospholipase activity
GO:0010720 positive regulation of cell development
GO:0010721 negative regulation of cell development
GO:0010863 positive regulation of phospholipase C activity
GO:0010975 regulation of neuron projection development
GO:0010976 positive regulation of neuron projection development
GO:0010977 negative regulation of neuron projection development
GO:0014003 oligodendrocyte development
GO:0014812 muscle cell migration
GO:0014909 smooth muscle cell migration
GO:0014910 regulation of smooth muscle cell migration
GO:0014911 positive regulation of smooth muscle cell migration
GO:0016358 dendrite development
GO:0021537 telencephalon development
GO:0021545 cranial nerve development
GO:0021549 cerebellum development
GO:0021554 optic nerve development
GO:0021675 nerve development
GO:0021782 glial cell development
GO:0022037 metencephalon development
GO:0022038 corpus callosum development
GO:0022604 regulation of cell morphogenesis
GO:0030031 cell projection assembly
GO:0030038 contractile actin filament bundle assembly
GO:0030335 positive regulation of cell migration
GO:0030799 regulation of cyclic nucleotide metabolic process
GO:0030800 negative regulation of cyclic nucleotide metabolic process
GO:0030802 regulation of cyclic nucleotide biosynthetic process
GO:0030803 negative regulation of cyclic nucleotide biosynthetic process
GO:0030808 regulation of nucleotide biosynthetic process
GO:0030809 negative regulation of nucleotide biosynthetic process
GO:0030814 regulation of cAMP metabolic process
GO:0030815 negative regulation of cAMP metabolic process
GO:0030817 regulation of cAMP biosynthetic process
GO:0030818 negative regulation of cAMP biosynthetic process
GO:0030900 forebrain development
GO:0030902 hindbrain development
GO:0031032 actomyosin structure organization
GO:0031345 negative regulation of cell projection organization
GO:0031346 positive regulation of cell projection organization
GO:0032060 bleb assembly
GO:0032103 positive regulation of response to external stimulus
GO:0032147 activation of protein kinase activity
GO:0032231 regulation of actin filament bundle assembly
GO:0032233 positive regulation of actin filament bundle assembly
GO:0032956 regulation of actin cytoskeleton organization
GO:0032970 regulation of actin filament-based process
GO:0033674 positive regulation of kinase activity
GO:0035023 regulation of Rho protein signal transduction
GO:0035025 positive regulation of Rho protein signal transduction
GO:0040017 positive regulation of locomotion
GO:0042063 gliogenesis
GO:0042552 myelination
GO:0043122 regulation of I-kappaB kinase/NF-kappaB signaling
GO:0043123 positive regulation of I-kappaB kinase/NF-kappaB signaling
GO:0043149 stress fiber assembly
GO:0043405 regulation of MAP kinase activity
GO:0043406 positive regulation of MAP kinase activity
GO:0043410 positive regulation of MAPK cascade
GO:0044089 positive regulation of cellular component biogenesis
GO:0045665 negative regulation of neuron differentiation
GO:0045666 positive regulation of neuron differentiation
GO:0045860 positive regulation of protein kinase activity
GO:0045980 negative regulation of nucleotide metabolic process
GO:0046058 cAMP metabolic process
GO:0046390 ribose phosphate biosynthetic process
GO:0046578 regulation of Ras protein signal transduction
GO:0046579 positive regulation of Ras protein signal transduction
GO:0046683 response to organophosphorus
GO:0048709 oligodendrocyte differentiation
GO:0050768 negative regulation of neurogenesis
GO:0050769 positive regulation of neurogenesis
GO:0050773 regulation of dendrite development
GO:0050920 regulation of chemotaxis
GO:0050921 positive regulation of chemotaxis
GO:0051017 actin filament bundle assembly
GO:0051056 regulation of small GTPase mediated signal transduction
GO:0051057 positive regulation of small GTPase mediated signal transduction
GO:0051272 positive regulation of cellular component movement
GO:0051480 regulation of cytosolic calcium ion concentration
GO:0051482 positive regulation of cytosolic calcium ion concentration involved in phospholipase C-activating G-protein coupled signaling pathway
GO:0051492 regulation of stress fiber assembly
GO:0051493 regulation of cytoskeleton organization
GO:0051495 positive regulation of cytoskeleton organization
GO:0051496 positive regulation of stress fiber assembly
GO:0051961 negative regulation of nervous system development
GO:0051962 positive regulation of nervous system development
GO:0052652 cyclic purine nucleotide metabolic process
GO:0055074 calcium ion homeostasis
GO:0060191 regulation of lipase activity
GO:0060193 positive regulation of lipase activity
GO:0060326 cell chemotaxis
GO:0060996 dendritic spine development
GO:0060998 regulation of dendritic spine development
GO:0060999 positive regulation of dendritic spine development
GO:0061572 actin filament bundle organization
GO:0070482 response to oxygen levels
GO:0071396 cellular response to lipid
GO:0071453 cellular response to oxygen levels
GO:0071670 smooth muscle cell chemotaxis
GO:0071671 regulation of smooth muscle cell chemotaxis
GO:0071673 positive regulation of smooth muscle cell chemotaxis
GO:0071900 regulation of protein serine/threonine kinase activity
GO:0071902 positive regulation of protein serine/threonine kinase activity
GO:0072503 cellular divalent inorganic cation homeostasis
GO:0072507 divalent inorganic cation homeostasis
GO:0072522 purine-containing compound biosynthetic process
GO:1900006 positive regulation of dendrite development
GO:1900274 regulation of phospholipase C activity
GO:1900371 regulation of purine nucleotide biosynthetic process
GO:1900372 negative regulation of purine nucleotide biosynthetic process
GO:1900542 regulation of purine nucleotide metabolic process
GO:1900543 negative regulation of purine nucleotide metabolic process
GO:1901293 nucleoside phosphate biosynthetic process
GO:1904565 response to 1-oleoyl-sn-glycerol 3-phosphate
GO:1904566 cellular response to 1-oleoyl-sn-glycerol 3-phosphate
GO:2000147 positive regulation of cell motility
Molecular Function GO:0001965 G-protein alpha-subunit binding
GO:0005543 phospholipid binding
GO:0030165 PDZ domain binding
GO:0035727 lysophosphatidic acid binding
GO:0045125 bioactive lipid receptor activity
GO:0070915 lysophosphatidic acid receptor activity
Cellular Component GO:0030139 endocytic vesicle
GO:0030425 dendrite
GO:0043025 neuronal cell body
GO:0043197 dendritic spine
GO:0043198 dendritic shaft
GO:0044297 cell body
GO:0044309 neuron spine
GO:0098794 postsynapse
> KEGG and Reactome Pathway
 
KEGG hsa04015 Rap1 signaling pathway
hsa04080 Neuroactive ligand-receptor interaction
hsa04151 PI3K-Akt signaling pathway
hsa04540 Gap junction
Reactome R-HSA-373076: Class A/1 (Rhodopsin-like receptors)
R-HSA-418594: G alpha (i) signalling events
R-HSA-416476: G alpha (q) signalling events
R-HSA-388396: GPCR downstream signaling
R-HSA-500792: GPCR ligand binding
R-HSA-881907: Gastrin-CREB signalling pathway via PKC and MAPK
R-HSA-419408: Lysosphingolipid and LPA receptors
R-HSA-162582: Signal Transduction
R-HSA-372790: Signaling by GPCR
Summary
SymbolLPAR1
Namelysophosphatidic acid receptor 1
Aliases rec.1.3; vzg-1; Gpcr26; Mrec1.3; LPA1; endothelial differentiation, lysophosphatidic acid G-protein-coupled ......
Chromosomal Location9q
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between LPAR1 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.
Summary
SymbolLPAR1
Namelysophosphatidic acid receptor 1
Aliases rec.1.3; vzg-1; Gpcr26; Mrec1.3; LPA1; endothelial differentiation, lysophosphatidic acid G-protein-coupled ......
Chromosomal Location9q
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of LPAR1 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolLPAR1
Namelysophosphatidic acid receptor 1
Aliases rec.1.3; vzg-1; Gpcr26; Mrec1.3; LPA1; endothelial differentiation, lysophosphatidic acid G-protein-coupled ......
Chromosomal Location9q
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of LPAR1 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)1412-1.2160.0602
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)65-1.380.332
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)87-1.0920.314
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 916-0.2260.72
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-0.9450.587
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470.6840.757
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.2530.648
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15110.0510.968
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 11120.5720.664
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 48-0.4790.648
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 28-0.0260.985
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.7232.14e-06
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of LPAR1 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27733.72.711
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27593.73.40.31
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21174.804.81
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13117.707.71
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 91606.2-6.21
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59011.1-11.11
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38272.602.61
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22134.504.51
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolLPAR1
Namelysophosphatidic acid receptor 1
Aliases rec.1.3; vzg-1; Gpcr26; Mrec1.3; LPA1; endothelial differentiation, lysophosphatidic acid G-protein-coupled ......
Chromosomal Location9q
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of LPAR1. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolLPAR1
Namelysophosphatidic acid receptor 1
Aliases rec.1.3; vzg-1; Gpcr26; Mrec1.3; LPA1; endothelial differentiation, lysophosphatidic acid G-protein-coupled ......
Chromosomal Location9q
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of LPAR1. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by LPAR1.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolLPAR1
Namelysophosphatidic acid receptor 1
Aliases rec.1.3; vzg-1; Gpcr26; Mrec1.3; LPA1; endothelial differentiation, lysophosphatidic acid G-protein-coupled ......
Chromosomal Location9q
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of LPAR1. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolLPAR1
Namelysophosphatidic acid receptor 1
Aliases rec.1.3; vzg-1; Gpcr26; Mrec1.3; LPA1; endothelial differentiation, lysophosphatidic acid G-protein-coupled ......
Chromosomal Location9q
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of LPAR1 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolLPAR1
Namelysophosphatidic acid receptor 1
Aliases rec.1.3; vzg-1; Gpcr26; Mrec1.3; LPA1; endothelial differentiation, lysophosphatidic acid G-protein-coupled ......
Chromosomal Location9q
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between LPAR1 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolLPAR1
Namelysophosphatidic acid receptor 1
Aliases rec.1.3; vzg-1; Gpcr26; Mrec1.3; LPA1; endothelial differentiation, lysophosphatidic acid G-protein-coupled ......
Chromosomal Location9q
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting LPAR1 collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.